I think this is naive. A mushroom trip is fully metabolized and cleared in approximately 6-12 hours. Despite the similar levels of reduction in depressive symptoms for the subsequent weeks, the psilocin has been cleared on the day of, unlike prozac, and hasn't been stimulating 5HT2* at all for that afterglow and post-exposure period.
Nobody other than crazy micro-dosers is taking mushrooms often enough to cause a change in receptor density and those people are putting themselves at risk of valvopathy due to 5HT2a restructuring of the heart valves (which, as an aside, is turning out to be a problem for people on prozac and other long-term SSRIs).
A drug that is very occasional, point use, with no ongoing use, which has long term treatment results, is absolutely, utterly unlike prozac.
That aside, let's say for the sake of argument that the mechanism is similar for prozac; I think that's wrong (one additional explanation may actually be: https://www.sciencedirect.com/science/article/abs/pii/S15675... ) but whatever. If so, then psilocin is vastly superior to prozac because you are not required to have continuous exposure for the benefits, as the corresponding cost, withdrawal, sexual dysfunction, weight gain, heart issues, etc. are removed.
> Nobody other than crazy micro-dosers is taking mushrooms often enough to cause a change in receptor density
This is so frustrating to me. Why not just google it before you think you know more about this than someone studying it for ten years? Two things can change receptor density: time and dose.
A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain
https://pubmed.ncbi.nlm.nih.gov/33467676/
This is exactly why psychedelics last longer than prozac. It has less to do with half life and more to do with dose.
How is the mechanism not at least comparative to prozac since it is well know they both effect serotonin? The risk with psilocin is exactly the dose, as many people find out. And you thing there are not cardiac side effects from psychedelics?
A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability
https://psychiatryonline.org/doi/full/10.1176/appi.ajp.22010...
Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experience
https://pmc.ncbi.nlm.nih.gov/articles/PMC11698204/
Safety First: Potential Heart Health Risks of Microdosing
https://petrieflom.law.harvard.edu/2022/04/13/safety-first-p...